MRC1 and neoplasm: Importantly, ROCK-NMII also altered the tumour’s microenvironment by establishing immunosuppression (increased pro-tumourigenic CD206+ macrophages and FOXP3+ Tregs), suggesting a contribution to the cross-resistance to ICB (anti-PD-1) [68].